Amuc_1100: the protein doing the work

There is a puzzle at the heart of how Akkermansia muciniphila is used. The form studied in humans, and the form authorised in Europe, is pasteurised — heat-treated, non-living cells. How can dead bacteria do anything at all? The answer is one of the more satisfying results in the field, and it comes down to a single protein with an unglamorous name: Amuc_1100. Once you understand what it is and where it sits, the pasteurised paradox stops being a paradox.

A protein on the surface

Akkermansia is wrapped in an outer membrane, and studded into that membrane are proteins that face the outside world — the parts of the bacterium that physically touch the cells of your gut lining. Amuc_1100 is one of those outer-membrane proteins. It is not something the bacterium secretes or manufactures on demand; it is a structural fixture of the cell surface, present whether the cell is alive or not.

That last detail is the key to everything that follows. A surface protein does not need a living, metabolising cell to do its job. If its job is to make contact with the gut lining and trigger a response, then what matters is that the protein is present and correctly shaped — not that the bacterium around it is alive.

The 2017 experiment

In 2017, Hubert Plovier and colleagues set out to find what, specifically, inside Akkermansia was responsible for its metabolic effects. Working in obese and diabetic mice, they ran the kind of clean, dissecting experiment that makes a mechanism convincing (Plovier et al., 2017).

Two findings stood out. First, the pasteurised bacterium worked at least as well as the live one — heat-killing the cells did not abolish the benefit, and in places improved it. Second, when they isolated Amuc_1100 and gave it on its own — no bacterium at all, just the purified protein — it reproduced much of the metabolic improvement. A single component, stripped out of the cell entirely, carried a large share of the effect the whole organism gets credit for.

That is how you know you have found something real. The benefit narrowed from "this bacterium" to "this protein on this bacterium's surface," and it survived the removal of everything else.

Why this solves the pasteurised paradox

If the active component is a heat-stable structural protein on the cell surface, then killing the cell is not a loss — pasteurisation leaves Amuc_1100 sitting on the surface, intact and able to make contact, while removing the unpredictability of administering a living microbe. The pasteurised-paradox story is covered in full elsewhere; Amuc_1100 is the molecular reason it works.

This also explains why preservation matters so much for us. If the value lives in a surface protein, the entire goal of processing is to keep that protein intact and correctly folded — which is exactly what gentle, heat-free freeze-drying is good at.

The human follow-on, and the honest edge

The Amuc_1100 work is mouse research, and we label it as such. But the story did not stop in mice: the first human trial in 32 overweight, insulin-resistant adults found the pasteurised form safe and showing the clearest metabolic improvements of the groups studied (Depommier et al., 2019). The lab's prediction held up when it reached people.

That human trial was small and exploratory, the protein-specific mechanism is still mostly animal-derived, and we don't turn any of that into a product claim. What it is, is an unusually well-traced explanation of why the pasteurised form is the one studied and authorised.

In the next post, we follow the berry side of the formula and the polyphenol trail that connects it back to this same bacterium.